0001493152-22-007099 | 10-Q | XBRL Viewer

Print Document View Excel Document

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jan. 31, 2022	Oct. 31, 2021
Current assets:
Cash and cash equivalents	$ 36,480	$ 41,614
Restricted cash	5,250
Prepaid expenses and other current assets	1,386	1,643
Total current assets	43,116	43,257
Property and equipment (net of accumulated depreciation)	100	118
Intangible assets (net of accumulated amortization)	3,238	3,354
Operating right-of-use asset (net of accumulated amortization)	33	40
Other assets	11	11
Total assets	46,498	46,780
Current liabilities:
Accounts payable	345	87
Accrued expenses	2,131	2,836
Current portion of operating lease liability	29	28
Preferred stock redemption liability	87
Common stock warrant liability	1,127	4,929
Total current liabilities	3,719	7,880
Operating lease liability, net of current portion	5	12
Total liabilities	3,724	7,892
Contingencies – Note 10
Series D convertible preferred stock- $0.001 par value; 1,000,000 shares authorized, issued and outstanding at January 31, 2022; Liquidation preference of $5,250 at January 31, 2022.	4,225
Stockholders’ equity:
Preferred stock, $0.001 par value; 4,000,000 and 5,000,000 shares authorized, 0 shares issued and outstanding at January 31, 2022 and October 31, 2021.
Common stock - $0.001 par value; 170,000,000 shares authorized, 145,638,459 shares issued and outstanding at January 31, 2022 and October 31, 2021.	146	146
Additional paid-in capital	467,368	467,342
Accumulated deficit	(428,965)	(428,600)
Total stockholders’ equity	38,549	38,888
Total liabilities and stockholders’ equity	$ 46,498	$ 46,780

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jan. 31, 2022	Oct. 31, 2021
Preferred Stock, Liquidation Preference, Value	$ 5,250
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	4,000,000	5,000,000
Preferred Stock, Shares Outstanding	0	0
Preferred Stock, Shares Issued	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	170,000,000	170,000,000
Common stock, shares issued	145,638,459	145,638,459
Common stock, shares outstanding	145,638,459	145,638,459
Series D Convertible Redeemable Preferred Stock [Member]
Temporary Equity, Par or Stated Value Per Share	$ 0.001	$ 0.001
Temporary Equity, Shares Authorized	1,000,000	1,000,000

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Income Statement [Abstract]
Revenue		$ 1,615
Operating expenses:
Research and development expenses	1,654	2,570
General and administrative expenses	2,510	3,008
Total operating expenses	4,164	5,578
Loss from operations	(4,164)	(3,963)
Other income (expense):
Interest income, net	1	1
Net changes in fair value of derivative liabilities	3,802	(27)
Other (expense) income	(4)	12
Net loss before income taxes	(365)	(3,977)
Income tax expense
Net loss	$ (365)	$ (3,977)
Net loss per common share, basic and diluted	$ (0.00)	$ (0.05)
Weighted average number of common shares, basic and diluted	145,638,459	83,943,982

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
OPERATING ACTIVITIES
Net loss	$ (365)	$ (3,977)
Adjustments to reconcile net loss to net cash used in operating activities:
Share based compensation	26	236
(Gain) loss on change in value of warrants	(3,802)	27
Loss on disposal of property and equipment		12
Abandonment of intangible assets	104
Depreciation expense	18	192
Amortization expense of intangible assets	70	67
Amortization of right-of-use asset	7	195
Change in operating assets and liabilities:
Prepaid expenses, other current assets and deferred expenses	257	463
Accounts payable and accrued expenses	(447)	394
Deferred revenue		(165)
Operating lease liabilities	(6)	(230)
Net cash used in operating activities	(4,138)	(2,786)
INVESTING ACTIVITIES
Cost of intangible assets	(58)	(210)
Net cash used in investing activities	(58)	(210)
FINANCING ACTIVITIES
Net proceeds of issuance of Series D preferred stock	4,312
Net proceeds of issuance of common stock and warrants		8,550
Warrant exercises		2,586
Net cash provided by financing activities	4,312	11,136
Net increase in cash, cash equivalents and restricted cash	116	8,140
Cash, cash equivalents and restricted cash at beginning of year	41,614	25,178
Total cash, cash equivalents and restricted cash shown in condensed statements of cash flows	41,730	33,318
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed balance sheets that sum to the total of the same such amounts shown in the condensed statements of cash flows:
Cash and cash equivalents	36,480	33,318
Restricted cash	5,250
SUPPLEMENTAL CASH FLOW INFORMATION
Cash paid for taxes

NATURE OF OPERATIONS

3 Months Ended

Jan. 31, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NATURE OF OPERATIONS

1. NATURE OF OPERATIONS

Advaxis, Inc. (“Advaxis” or the “Company”) is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (“Lm”)-based antigen delivery products. The Company is using its Lm platform directed against tumor-specific targets in order to engage the patient’s immune system to destroy tumor cells. Through a license from the University of Pennsylvania, Advaxis has exclusive access to this proprietary formulation of attenuated Lm called Lm Technology^TM. Advaxis’ proprietary approach is designed to deploy a unique mechanism of action that redirects the immune system to attack cancer in three distinct ways:

	●	Alerting and training the immune system by activating multiple pathways in Antigen-Presenting Cells (“APCs”) with the equivalent of multiple adjuvants;
	●	Attacking the tumor by generating a strong, cancer-specific T cell response; and
	●	Breaking down tumor protection through suppression of the protective cells in the tumor microenvironment (“TME”) that shields the tumor from the immune system. This enables the activated T cells to begin working to attack the tumor cells.

Advaxis’ proprietary Lm platform technology has demonstrated clinical activity in several of its programs and has been dosed in over 470 patients across multiple clinical trials and in various tumor types. The Company believes that Lm Technology immunotherapies can complement and address significant unmet needs in the current oncology treatment landscape. Specifically, its product candidates have the potential to work synergistically with other immunotherapies, including checkpoint inhibitors, while having a generally well-tolerated safety profile.

Liquidity and Capital Resources

Liquidity and Management’s Plans

Similar to other development stage biotechnology companies, the Company’s products that are being developed have not generated significant revenue. As a result, the Company has suffered recurring losses and requires significant cash resources to execute its business plans. These losses are expected to continue for the foreseeable future.

As of January 31, 2022, the Company had approximately $36.5 million in cash and cash equivalents. Although the Company expects to have sufficient capital to fund its obligations, as they become due, in the ordinary course of business until at least one year from the issuance of these consolidated financial statements, the actual amount of cash that it will need to operate is subject to many factors.

The Company recognizes it will need to raise additional capital in order to continue to execute its business plan in the future. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to further scale back its operations.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

3 Months Ended

Jan. 31, 2022

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

Basis of Presentation/Estimates

The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) with respect to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and the accompanying unaudited interim condensed consolidated balance sheet as of January 31, 2022 has been derived from the Company’s October 31, 2021 audited financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements furnished include all adjustments (consisting of normal recurring accruals) necessary for a fair statement of the results for the interim periods presented.

Operating results for interim periods are not necessarily indicative of the results to be expected for the full year. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates include the timelines associated with revenue recognition on upfront payments received, fair value and recoverability of the carrying value of property and equipment and intangible assets, fair value of warrant liability, grant date fair value of options, deferred tax assets and any related valuation allowance and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from these estimates.

These unaudited interim condensed consolidated financial statements should be read in conjunction with the financial statements of the Company as of and for the fiscal year ended October 31, 2021 and notes thereto contained in the Company’s 2021 Annual Report on Form 10-K, as filed with the SEC on February 14, 2022.

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated.

Restricted Cash

On January 31, 2022, the Company transferred $5,250,000 into an escrow fund to fund a potential Series D preferred stock redemption.

Convertible Preferred Stock

Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. The Company classifies conditionally redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control, as temporary equity (“mezzanine”) until such time as the conditions are removed or lapse.

Derivative Financial Instruments

The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For share-based derivative financial instruments, the Company used the Monte Carlo simulation model, the Black Scholes model and a binomial model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the consolidated balance sheet as current or non-current based on whether or not net-cash settlement of the instrument could be required within 12 months after the balance sheet date.

Net Income (Loss) per Share

Basic net income or loss per common share is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, restricted stock units and other potential common stock outstanding during the period. In the case of a net loss, the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income, the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table below sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share:

	As of January 31,
	2022		2021
Warrants		30,225,397		8,014,220
Series D convertible redeemable preferred stock		20,000,000		-
Stock options		888,058		1,047,377
Restricted stock units		-		5,556
Total		51,113,455		9,067,153

Recent Accounting Standards

In December 2019, the FASB issued ASU 2019-12, Simplification of Income Taxes (Topic 740) Income Taxes (“ASU 2019-12”). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for public companies for annual periods beginning after December 15, 2020, including interim periods within those fiscal years. The Company adopted this standard effective November 1, 2021 and it is not material to the financial results of the Company.

In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain convertible instruments, amends guidance on derivative scope exceptions for contracts in an entity’s own equity, and modifies the guidance on diluted earnings per share (“EPS”) calculations as a result of these changes. The standard will be effective for the Company for fiscal years beginning after December 15, 2023 and can be applied on either a fully retrospective or modified retrospective basis. Early adoption is permitted for fiscal years beginning after December 15, 2020. The Company adopted this standard effective November 1, 2021 and it is not material to the financial results of the Company.

Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed consolidated financial statements.

PROPERTY AND EQUIPMENT

3 Months Ended

Jan. 31, 2022

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT

3. PROPERTY AND EQUIPMENT

Property and equipment, net consisted of the following (in thousands):

SCHEDULE OF PROPERTY AND EQUIPMENT

	January 31, 2022			October 31, 2021
Laboratory equipment	$	179		$	179
Computer equipment		241			241
Total property and equipment		420			420
Accumulated depreciation and amortization		(320	)		(302	)
Net property and equipment	$	100		$	118

Depreciation expense for the three months ended January 31, 2022 and 2021 was approximately $18,000 and $192,000, respectively.

INTANGIBLE ASSETS

3 Months Ended

Jan. 31, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

INTANGIBLE ASSETS

4. INTANGIBLE ASSETS

Intangible assets, net consisted of the following (in thousands):

SUMMARY OF INTANGIBLE ASSETS

	January 31, 2022			October 31, 2021

Patents	$	4,769		$	4,836
Licenses		777			777
Software		98			98
Total intangibles		5,644			5,711
Accumulated amortization		(2,406	)		(2,357	)
Intangible assets	$	3,238		$	3,354

The expiration dates of the existing patents range from 2021 to 2039 but the expiration dates can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to further pursue the application. Patent applications having a net book value of approximately $104,000 and $0 were abandoned and were charged to general and administrative expenses in the statement of operations for each of the three months ended January 31, 2022 and 2021, respectively. Amortization expense for intangible assets that was charged to general and administrative expense in the statement of operations aggregated approximately $70,000 and $67,000 for the three months ended January 31, 2022 and 2021, respectively.

Management has reviewed its long-lived assets for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable. Net assets are recorded on the balance sheet for patents and licenses related to axalimogene filolisbac (AXAL), ADXS-HOT, ADXS-PSA and other products that are in development. However, if a competitor were to gain FDA approval for a similar treatment before the Company or if future clinical trials fail to meet the targeted endpoints, the Company will likely record an impairment related to these assets. In addition, if an application is rejected or fails to be issued, the Company would record an impairment of its estimated book value. Lastly, if the Company is unable to raise enough capital to continue funding its studies and developing its intellectual property, the Company would likely record an impairment to these assets.

As of January 31, 2022, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands):

	Fiscal year ending October 31,

2022 (Remaining)	$	211
2023		282
2024		282
2025		282
2026		282
Thereafter		1,899
Total	$	3,238

ACCRUED EXPENSES

3 Months Ended

Jan. 31, 2022

Payables and Accruals [Abstract]

ACCRUED EXPENSES

5. ACCRUED EXPENSES:

The following table summarizes accrued expenses included in the condensed consolidated balance sheets (in thousands):

SUMMARY OF ACCRUED EXPENSES

	January 31, 2022		October 31, 2021

Salaries and other compensation	$	170	$	55
Vendors		1,524		1,968
Professional fees		237		613
Other		200		200
Total accrued expenses	$	2,131	$	2,836

LEASES

3 Months Ended

Jan. 31, 2022

Leases

LEASES

6. LEASES

Operating Leases

The Company previously leased a corporate office and manufacturing facility in Princeton, New Jersey under an operating lease that was set to expire in November 2025. On March 26, 2021, the Company entered into a Lease Termination and Surrender Agreement with respect to this lease agreement. The Lease Termination and Surrender Agreement provides for the early termination of the lease, which became effective on March 31, 2021. In connection with the early termination of the lease, the Company was required to pay a $1,000,000 termination payment. The unapplied security deposit totaling approximately $182,000 was credited against the termination fee for a net payment of approximately $818,000. The Company wrote off of the remaining right-of-use asset of approximately $4.5 million and lease liability of approximately $5.6 million. After consideration of the termination payment and write off of remaining right-of-use asset and lease liability, the Company recorded a net gain of approximately $0.1 million.

On March 25, 2021, the Company entered into a new lease agreement for its corporate office/lab with base rent of approximately $29,000 per year, plus other expenses. The lease expires on March 25, 2022 and the Company has the option to renew the lease for one additional successive one-year term upon six months written notice to the landlord. This new lease was accounted for as a short-term lease at inception, and the Company elected not to recognize a right-of-use asset and lease liability. In September 2021, the Company exercised its option to renew the lease, extending the lease term until March 25, 2023. Since the renewed lease term exceeds one-year, the lease no longer qualifies for the short-term lease exception, resulting in the recognition of a right-of-use asset and operating lease liability of approximately $43,000.

Supplemental balance sheet information related to leases was as follows (in thousands):

	January 31, 2022		October 31, 2021
Operating leases:
Operating lease right-of-use assets	$	33	$	40

Operating lease liability	$	29	$	28
Operating lease liability, net of current portion		5		12
Total operating lease liabilities	$	34	$	40

Supplemental lease expense related to leases was as follows (in thousands):

SCHEDULE OF LEASE EXPENSES

Lease Cost (in thousands)	Statements of Operations Classification	For the Three Months Ended January 31, 2022		For the Three Months Ended January 31, 2021
Operating lease cost	General and administrative		7		290
Variable lease cost	General and administrative	$	9		437
Total lease expense		$	16		727

Other information related to leases where the Company is the lessee is as follows:

	January 31, 2022			October 31, 2021
Weighted-average remaining lease term		1.2 years			1.4 years
Weighted-average discount rate		3.79	%		3.79	%

Supplemental cash flow information related to operating leases was as follows:

		For the Three Months Ended January 31, 2022				For the Three Months Ended January 31, 2021
Cash paid for operating lease liabilities		$	7			$	324

Future minimum lease payments under non-cancellable leases as of January 31, 2022 were as follows:

Fiscal Year ending October 31,
2022 (Remaining)	$	22
2023		13
Total minimum lease payments		35
Less: Imputed interest		(1	)
Total	$	34

COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY

3 Months Ended

Jan. 31, 2022

Common Stock Purchase Warrants And Warrant Liability

COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY

7. COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY

Warrants

As of January 31, 2022 and October 31, 2021, there were outstanding and exercisable warrants to purchase 30,225,397 shares of our common stock with exercise prices ranging from $0.30 to $281.25 per share. Information on the outstanding warrants is as follows:

Exercise Price		Number of Shares Underlying Warrants		Expiration Date	Type of Financing
$	281.25		25	N/A	Other warrants
$	0.25		70,297	July 2024	September 2018 Public Offering
$	2.80		327,338	September 2024	July 2019 Public Offering
$	0.35		4,578,400	November 2025	November 2020 Public Offering
$	0.70		11,244,135	April 2026	April 2021 Registered Direct Offering (Accompanying Warrants)
$	0.70		14,005,202	5 years after the date such warrants become exercisable, if ever	April 2021 Private Placement (Private Placement Warrants)
	Grand Total		30,225,397

As of January 31, 2022 and October 31, 2021, the Company had 16,149,898 of its total 30,225,397 outstanding warrants classified as equity (equity warrants).

Warrant Liability

As of January 31, 2022 and October 31, 2021, the Company had 14,075,499 of its total 30,225,397 outstanding warrants from an April 2021 private offering of common stock and warrants (the “April 2021 Private Placement”) and a September 2018 public offering of common stock and warrants (the “September 2018 Public Offering”) classified as liabilities (liability warrants).

The warrants issued in the April 2021 Private Placement will become exercisable only on such day, if ever, that is 14 days after the Company files an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock, $0.001 par value per share from 170,000,000 shares to 300,000,000 shares. These warrants expire five years after the date they become exercisable. As of January 31, 2022, the Company did not have sufficient authorized common stock to allow for the issuance of common stock underlying these warrants. The Company did not receive stockholder authorization to increase the authorized shares from 170,000,000 to 300,000,000 shares at the stockholder’s meeting commenced on June 3, 2021. The Company was subsequently required to file a proxy to seek an increase in the number of authorized shares and did not file such a proxy but rather elected to seek a reverse stock split to, among other things, increase the shares available. Accordingly, based on certain indemnification provisions of the securities purchase agreement, the Company concluded that liability classification is warranted. The Company utilized the Black Scholes model to calculate the fair value of these warrants at issuance and at each subsequent reporting date.

In measuring the warrant liability for the warrants issued in the April 2021 Private Placement at January 31, 2022 and October 31, 2021, the Company used the following inputs in its Black Scholes model:

	January 31, 2022			October 31, 2021
Exercise Price	$	0.70		$	0.70
Stock Price	$	0.136		$	0.485
Expected Term		5.00 years			5.00 years
Volatility %		108	%		106	%
Risk Free Rate		1.62	%		1.18	%

The September 2018 Public Offering warrants contain a down round feature, except for exempt issuances as defined in the warrant agreement, in which the exercise price would immediately be reduced to match a dilutive issuance of common stock, options, convertible securities and changes in option price or rate of conversion. As of January 31, 2021, the down round feature was triggered four times and the exercise price of the warrants were reduced from $22.50 to $0.25. The warrants require liability classification as the warrant agreement requires the Company to maintain an effective registration statement and does not specify any circumstances under which settlement in other than cash would be permitted or required. As a result, net cash settlement is assumed and liability classification is warranted. For these liability warrants, the Company utilized the Monte Carlo simulation model to calculate the fair value of these warrants at issuance and at each subsequent reporting date.

In measuring the warrant liability for the September 2018 Public Offering warrants at January 31, 2022 and October 31, 2021, the Company used the following inputs in its Monte Carlo simulation model:

	January 31, 2022			October 31, 2021
Exercise Price	$	0.25		$	0.30
Stock Price	$	0.136		$	0.485
Expected Term		2.61 years			2.87 years
Volatility %		118	%		123	%
Risk Free Rate		1.29	%		0.77	%

At January 31, 2022 and October 31, 2021, the fair value of the warrant liability was approximately $1,127,000 and $4,929,000, respectively. For the three months ended January 31, 2022 and 2021, the Company reported income of approximately $3,802,000 and expense of $27,000, respectively, due to changes in the fair value of the warrant liability.

COMMITMENTS AND CONTINGENCIES

3 Months Ended

Jan. 31, 2022

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

8. COMMITMENTS AND CONTINGENCIES

Atachbarian

On November 15, 2021, a purported stockholder of the Company commenced an action against the Company and certain of its directors in the U.S. District Court for the District of New Jersey, entitled Atachbarian v. Advaxis, Inc., et al., No. 3:21-cv-20006. The plaintiff alleges that the defendants breached their fiduciary duties and violated Section 14(a) and Rule 20(a) of the Securities Exchange Act of 1934 and Rule 14a-9 promulgated thereunder by allegedly failing to disclose certain matters in its Registration Statement on Form S-4 (Commission File No. 333-259065 (the “Registration Statement”) filed in connection with a proposed merger with Biosight Ltd. (the “Previously Proposed Merger”). On December 15, 2021, pursuant to an understanding reached with the plaintiff, the Company made certain other additional disclosures that mooted the demands asserted in the complaint. On December 17, 2021, the plaintiff filed a notice of voluntary dismissal with prejudice. On February 7, 2022, the Company and the plaintiff reached a settlement agreement, which is recorded in accrued expenses in the consolidated balance statement.

Purported Stockholder Claims Related to Biosight Transaction

Between September 16, 2021, and November 4, 2021, the Company received demand letters on behalf of six purported stockholders of the Company, alleging that the Company failed to disclose certain matters in the Registration Statement, and demanding that the Company disclose such information in a supplemental disclosure filed with the SEC. On October 14, 2021, the Company filed an amendment to the Registration Statement and on November 8, 2021, the Company made certain other additional disclosures that mooted the demands asserted in the above-referenced letters. The six plaintiffs have made a settlement demand. The Company believes it has adequately accrued for a settlement, which is recorded in accrued expenses in the consolidated balance sheet.

In addition, the Company received certain additional demands from stockholders asserting that the proxy materials filed by the Company in connection with the Previously Proposed Merger contained alleged material misstatements and/or omissions in violation of federal law. In response to these demands, the Company agreed to make, and did make, certain supplemental disclosures to the proxy materials. At this time, the Company is unable to predict the likelihood of an unfavorable outcome.

TEMPORARY EQUITY

3 Months Ended

Jan. 31, 2022

Temporary Equity

TEMPORARY EQUITY

9. TEMPORARY EQUITY

Series D Convertible Preferred Stock Offering

On January 31, 2022, the Company closed on an offering with certain institutional investors for the private placement of 1,000,000 shares of Series D convertible redeemable preferred stock (“Series D preferred stock”). The shares to be sold have an aggregate stated value of $5,000,000. Each share of the Series D preferred stock has a purchase price of $4.75, representing an original issue discount of 5% of the stated value. Total net proceeds from the offering, after deducting the financial advisor’s fees and other estimated offering expenses, were approximately $4,312,000.

The Company has called a special meeting of stockholders to consider an amendment (the “Amendment”) to the Company’s Amended and Restated Certificate of Incorporation, to effect a reverse stock split of the outstanding shares of common stock by a ratio to be determined by the Board of Directors of the Company within a range to be specified in the proposal put to the stockholders for approval of the Amendment. The investors have agreed in the Purchase Agreement to not transfer, offer, sell, contract to sell, hypothecate, pledge or otherwise dispose of the shares of the Series D preferred stock until the reverse stock split and to vote the shares of the Series D preferred stock purchased in the offering in a manner that “mirrors” the proportions on which the shares of common stock (excluding any shares of common stock that are not voted) are voted on the reverse stock split and the Amendment. The Amendment requires the approval of the majority of the votes associated with the Company’s outstanding stock entitled to vote on the proposal. The certificate of designation provides that the Series D preferred stock will have no voting rights, other than the right to vote as a class on certain specified matters, except that each share of Series D preferred stock will have the right to cast 30,000 votes per share of Series D preferred stock on the reverse stock split.

The Series D preferred stock can be converted at the option of the holder at any time after the Company has received stockholder approval for a reverse stock split and filed the requisite amendment with the Delaware Secretary of State’s office to effectuate the reverse stock split, subject to beneficial ownership limitations. The Company will be permitted to compel conversion of the Series D preferred stock after the fulfillment of certain conditions and subject to certain limitations. The Series D preferred stock is convertible into shares of Common Stock at a rate of $0.25 per share for the Series D preferred stock. In addition, on or after the reverse stock split date, and subject to the satisfaction of certain conditions, the Company can cause the holder of the Series D Preferred Stock to convert their shares of Series D Preferred Stock, subject to such beneficial ownership limitations.

The Series D preferred stock has a liquidation preference over the common stock, and may be redeemed by the investors. Each holder of the Series D preferred stock has the right to cause the Company to redeem all or part of their shares of the Series D preferred stock from the earlier of receipt of stockholder approval of the reverse stock split or 90 days following the original issue date until 120 days following the original issue date (the “Redemption Date”) in cash at a redemption price equal to 105% of the stated value plus an amount equal to accumulated but unpaid dividends, if any, on such shares (whether or not earned or declared, but excluding interest on such dividends) up to, but excluding, the Redemption Date. Under certain circumstances, the commencement of the period during which the Series D preferred stock may be redeemed may be extended from 90 days following the original issue date to 135 days following the original issue date, in which case the Redemption Date would be extended to 165 days following the original issue date. Should such extension occur, the redemption price would be increased to an amount equal to 110% of the stated value plus an amount equal to accumulated but unpaid dividends, if any, on such shares.

The holders of Series D preferred stock will be entitled to dividends, on an as-if converted basis, equal to dividends actually paid, if any, on shares of common stock.

The $4.75 million in gross proceeds of the offering are held in an escrow account, along with an additional $500,000 deposited by the Company to cover the aggregate original issue discount as well as the additional amount that would be necessary to fund the 105% redemption price until the expiration of the redemption period for the Series D Preferred Stock, as applicable, subject to the earlier payment to redeeming holders. Upon expiration of the redemption period, any proceeds remaining in escrow will be disbursed to the Company.

In connection with the Offering, the Company and the investors entered into a registration rights agreement, pursuant to which the Company is required to file a registration statement with the Securities and Exchange Commission to register for resale the shares that are issued upon the conversion of shares of Series D preferred stock. The registration statement will be filed with the Securities and Exchange Commission on or before the 60th calendar day following the first date on which shares are issued upon the conversion of shares of Series D preferred stock.

Since the Series D preferred stock has a redemption feature at the option of the holder, it is classified as temporary equity. At the January 31, 2022 issuance date, the Series D preferred stock was recorded on the balance sheet at approximately $4,225,000, which is the $4,312,000 net proceeds less the $87,000 value of the bifurcated preferred stock redemption liability (see below).

Preferred Stock Redemption Liability

The Company evaluated the preferred stock redemption feature under ASC 815. Since the preferred stock redemption feature is not considered to be clearly and closely related to the preferred stock host and the redemption feature meets the four characteristics of a derivative under ASC 815, the preferred stock redemption feature is required to be bifurcated from the preferred stock host and valued as a liability. The Company utilized a binomial model to calculate the fair value of the preferred stock redemption feature at issuance.

In measuring the preferred stock redemption liability at January 31, 2022 (issuance date), the Company used the following inputs in its binomial model:

	January 31, 2022
Exercise Price	$	0.25
Stock Price	$	0.136
Volatility %		105	%
Risk Free Rate		1.00	%

At January 31, 2022, the fair value of the preferred stock redemption liability was approximately $87,000.

STOCKHOLDERS’ EQUITY

3 Months Ended

Jan. 31, 2022

Equity [Abstract]

STOCKHOLDERS’ EQUITY

10. STOCKHOLDERS’ EQUITY

A summary of the changes in stockholders’ equity for the three months ended January 31, 2022 and 2021 is presented below (in thousands, except share data):

SUMMARY OF STOCKHOLDERS EQUITY

	Shares		Amount		Shares		Amount		Capital		Deficit			Equity
	Preferred Stock				Common Stock				Additional Paid-In		Accumulated			Total Shareholders’
	Shares		Amount		Shares		Amount		Capital		Deficit			Equity
Balance at November 1, 2020		-	$	-		78,074,023	$	78	$	440,840	$	(410,738	)	$	30,180
Beginning balance, value		-	$	-		78,074,023	$	78	$	440,840	$	(410,738	)	$	30,180
Stock-based compensation		-		-		-		-		236		-			236
Advaxis public offerings, net of offering costs		-		-		30,666,665		31		8,519		-			8,550
Warrant exercises		-		-		7,390,000		7		2,579		-			2,586
Net Loss		-		-		-		-		-		(3,977	)		(3,977	)
Balance at January 31, 2021		-	$	-		116,130,688	$	116	$	452,174	$	(414,715	)	$	37,575
Ending balance , value		-	$	-		116,130,688	$	116	$	452,174	$	(414,715	)	$	37,575

	Preferred Stock				Common Stock				Additional Paid-In		Accumulated			Total Shareholders’
	Shares		Amount		Shares		Amount		Capital		Deficit			Equity
Balance at November 1, 2021		-	$	-		145,638,459	$	146	$	467,342	$	(428,600	)	$	38,888
Beginning balance, value		-	$	-		145,638,459	$	146	$	467,342	$	(428,600	)	$	38,888
Stock-based compensation		-		-		-		-		26		-			26
Net Loss		-		-		-		-		-		(365	)		(365	)
Balance at January 31, 2022		-	$	-		145,638,459	$	146	$	467,368	$	(428,965	)	$	38,549
Ending balance, value		-	$	-		145,638,459	$	146	$	467,368	$	(428,965	)	$	38,549

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

SHARE BASED COMPENSATION

3 Months Ended

Jan. 31, 2022

Share-based Payment Arrangement [Abstract]

SHARE BASED COMPENSATION

11. SHARE BASED COMPENSATION

The following table summarizes share-based compensation expense included in the condensed consolidated statements of operations (in thousands):

	Three Months Ended January 31,
	2022		2021
Research and development	$	13	$	57
General and administrative		13		179
Total	$	26	$	236

Stock Options

A summary of changes in the stock option plan for the three months ended January 31, 2022 is as follows:

SUMMARY OF CHANGES IN STOCK OPTION PLAN

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value (in thousands)
Outstanding as of October 31, 2021		893,946		$	19.32		7.80	$	27
Cancelled or expired		(5,888	)		277.50
Outstanding as of January 31, 2022		888,058		$	17.61		7.55	$	-
Vested and exercisable at January 31, 2022		484,641		$	31.80		6.89	$	-

The following table summarizes information about the outstanding and exercisable options at January 31, 2022:

Options Outstanding								Options Exercisable
				Weighted		Weighted				Weighted		Weighted
				Average		Average				Average		Average
Exercise		Number		Remaining		Exercise		Number		Remaining		Exercise
Price Range		Outstanding		Contractual		Price		Exercisable		Contractual		Price
$	.30-$1.00		672,500		8.29	$	0.54		270,000		8.20	$	0.50
$	1.01-$10.00		55,379		6.80	$	7.47		54,462		6.79	$	7.56
$	10.01-$100.00		90,432		5.97	$	29.02		90,432		5.97	$	29.02
$	100.01-$258.30		69,747		3.07	$	175.51		69,747		3.07	$	175.51

As of January 31, 2022, there was approximately $125,000 of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining weighted average vesting period of 1.38 years.

Potential Acceleration of Stock Options

In the event of a merger transaction, similar to the Previously Proposed Merger Agreement, all of the Chief Executive Officer’s 73,777 unvested stock options, pursuant to his employment agreement, would accelerate.

LICENSING AGREEMENTS

3 Months Ended

Jan. 31, 2022

Licensing Agreements

LICENSING AGREEMENTS

12. LICENSING AGREEMENTS

OS Therapies LLC

On September 4, 2018, the Company entered into a development, license and supply agreement with OS Therapies (“OST”) for the use of ADXS31-164, also known as ADXS-HER2, for evaluation in the treatment of osteosarcoma in humans. Under the terms of the license agreement, as amended, OST will be responsible for the conduct and funding of a clinical study evaluating ADXS-HER2 in recurrent, completely resected osteosarcoma. Under the most recent amendment to the licensing agreement, OST agreed to pay Advaxis $25,000 per month (“Monthly Payment”) starting on April 30, 2020 until it achieved its funding milestone of $2,337,500. Upon receipt of the first Monthly Payment, Advaxis initiated the transfer of the intellectual property and licensing rights of ADXS31-164, which were licensed pursuant to the Penn Agreement, back to the University of Pennsylvania. Contemporaneously, OST will enter negotiations with the University of Pennsylvania to establish a licensing agreement for ADXS31-164 to OST for clinical and commercial development of the ADXS31-164 technology.

During the three months ended January 31, 2021, the Company received an aggregate of $1,615,000 from OS Therapies upon achievement of the funding milestone set forth in the license agreement. The Company therefore transferred and OST took full ownership of the IND application for ADXS31-164 in its entirety along with agreements and promises contained therein, as well as all obligations associated with this IND or any HER2 product/program development.

FAIR VALUE

3 Months Ended

Jan. 31, 2022

Fair Value Disclosures [Abstract]

FAIR VALUE

13. FAIR VALUE

The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

● Level 1 — Quoted prices in active markets for identical assets or liabilities.

● Level 2— Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities.

● Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities.

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of January 31, 2022 and October 31, 2021 (in thousands):

	Level 1		Level 2		Level 3		Total
Fair value measured at January 31, 2022
	Level 1		Level 2		Level 3		Total
Financial assets at fair value:
Cash equivalents (money market funds)	$	17,154	$	-	$	-	$	17,154
Total Financial Assets at Fair Value	$	17,154	$	-	$	-	$	17,154

Financial liabilities at fair value:
Preferred stock redemption liability	$	-	$	-	$	87	$	87
Common stock warrant liability, warrants exercisable at $0.25 through September 2024		-		-		7		7
Common stock warrant liability, warrants exercisable at $0.70 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)		-		-		1,120		1,120
Total financial liabilities at fair value	$	-	$	-	$	1,214	$	1,214

	Level 1		Level 2		Level 3		Total
Fair value measured at October 31, 2021
	Level 1		Level 2		Level 3		Total
Financial assets at fair value:
Cash equivalents (money market funds)	$	17,153	$	-	$	-	$	17,153
Total Financial Assets at Fair Value	$	17,153	$	-	$	-	$	17,153

Financial liabilities at fair value:
Common stock warrant liability, warrants exercisable at $0.30 through September 2024	$	-	$	-	$	27	$	27
Common stock warrant liability, warrants exercisable at $0.70 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)		-		-		4,902		4,902
Total financial liabilities at fair value	$	-	$	-	$	4,929	$	4,929

The following table presents changes in Level 3 liabilities measured at fair value (in thousands) for the three months ended January 31, 2022. Unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category.

	Preferred Stock Redemption Liability		Warrant Liabilities			Total
Fair value at October 31, 2021	$	-	$	4,929		$	4,929
Additions		87		-			87
Change in fair value		-		(3,802	)		(3,802	)
Fair value at January 31, 2022	$	87	$	1,127		$	1,214

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Policies)

3 Months Ended

Jan. 31, 2022

Accounting Policies [Abstract]

Basis of Presentation/Estimates

Basis of Presentation/Estimates

Principles of Consolidation

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated.

Restricted Cash

Restricted Cash

On January 31, 2022, the Company transferred $5,250,000 into an escrow fund to fund a potential Series D preferred stock redemption.

Convertible Preferred Stock

Convertible Preferred Stock

Derivative Financial Instruments

Derivative Financial Instruments

Net Income (Loss) per Share

Net Income (Loss) per Share

	As of January 31,
	2022		2021
Warrants		30,225,397		8,014,220
Series D convertible redeemable preferred stock		20,000,000		-
Stock options		888,058		1,047,377
Restricted stock units		-		5,556
Total		51,113,455		9,067,153

Recent Accounting Standards

Recent Accounting Standards

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Tables)

3 Months Ended

Jan. 31, 2022

Accounting Policies [Abstract]

SCHEDULE OF ANTI -DILUTED SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE

	As of January 31,
	2022		2021
Warrants		30,225,397		8,014,220
Series D convertible redeemable preferred stock		20,000,000		-
Stock options		888,058		1,047,377
Restricted stock units		-		5,556
Total		51,113,455		9,067,153

PROPERTY AND EQUIPMENT (Tables)

3 Months Ended

Jan. 31, 2022

Property, Plant and Equipment [Abstract]

SCHEDULE OF PROPERTY AND EQUIPMENT

Property and equipment, net consisted of the following (in thousands):

SCHEDULE OF PROPERTY AND EQUIPMENT

	January 31, 2022			October 31, 2021
Laboratory equipment	$	179		$	179
Computer equipment		241			241
Total property and equipment		420			420
Accumulated depreciation and amortization		(320	)		(302	)
Net property and equipment	$	100		$	118

INTANGIBLE ASSETS (Tables)

3 Months Ended

Jan. 31, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

SUMMARY OF INTANGIBLE ASSETS

Intangible assets, net consisted of the following (in thousands):

SUMMARY OF INTANGIBLE ASSETS

	January 31, 2022			October 31, 2021

Patents	$	4,769		$	4,836
Licenses		777			777
Software		98			98
Total intangibles		5,644			5,711
Accumulated amortization		(2,406	)		(2,357	)
Intangible assets	$	3,238		$	3,354

SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS

As of January 31, 2022, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands):

	Fiscal year ending October 31,

2022 (Remaining)	$	211
2023		282
2024		282
2025		282
2026		282
Thereafter		1,899
Total	$	3,238

ACCRUED EXPENSES (Tables)

3 Months Ended

Jan. 31, 2022

Payables and Accruals [Abstract]

SUMMARY OF ACCRUED EXPENSES

The following table summarizes accrued expenses included in the condensed consolidated balance sheets (in thousands):

SUMMARY OF ACCRUED EXPENSES

	January 31, 2022		October 31, 2021

Salaries and other compensation	$	170	$	55
Vendors		1,524		1,968
Professional fees		237		613
Other		200		200
Total accrued expenses	$	2,131	$	2,836

LEASES (Tables)

3 Months Ended

Jan. 31, 2022

Leases

SCHEDULE OF SUPPLEMENTAL BALANCE SHEET RELATED TO LEASES

Supplemental balance sheet information related to leases was as follows (in thousands):

	January 31, 2022		October 31, 2021
Operating leases:
Operating lease right-of-use assets	$	33	$	40

Operating lease liability	$	29	$	28
Operating lease liability, net of current portion		5		12
Total operating lease liabilities	$	34	$	40

SCHEDULE OF LEASE EXPENSES

Supplemental lease expense related to leases was as follows (in thousands):

SCHEDULE OF LEASE EXPENSES

Lease Cost (in thousands)	Statements of Operations Classification	For the Three Months Ended January 31, 2022		For the Three Months Ended January 31, 2021
Operating lease cost	General and administrative		7		290
Variable lease cost	General and administrative	$	9		437
Total lease expense		$	16		727

SCHEDULE OF OTHER INFORMATION RELATED TO LEASES

Other information related to leases where the Company is the lessee is as follows:

	January 31, 2022			October 31, 2021
Weighted-average remaining lease term		1.2 years			1.4 years
Weighted-average discount rate		3.79	%		3.79	%

SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES

Supplemental cash flow information related to operating leases was as follows:

		For the Three Months Ended January 31, 2022				For the Three Months Ended January 31, 2021
Cash paid for operating lease liabilities		$	7			$	324

SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELLABLE LEASES

Future minimum lease payments under non-cancellable leases as of January 31, 2022 were as follows:

Fiscal Year ending October 31,
2022 (Remaining)	$	22
2023		13
Total minimum lease payments		35
Less: Imputed interest		(1	)
Total	$	34

COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Tables)

3 Months Ended

Jan. 31, 2022

Subsidiary, Sale of Stock [Line Items]

COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY

Exercise Price		Number of Shares Underlying Warrants		Expiration Date	Type of Financing
$	281.25		25	N/A	Other warrants
$	0.25		70,297	July 2024	September 2018 Public Offering
$	2.80		327,338	September 2024	July 2019 Public Offering
$	0.35		4,578,400	November 2025	November 2020 Public Offering
$	0.70		11,244,135	April 2026	April 2021 Registered Direct Offering (Accompanying Warrants)
$	0.70		14,005,202	5 years after the date such warrants become exercisable, if ever	April 2021 Private Placement (Private Placement Warrants)
	Grand Total		30,225,397

SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY

In measuring the warrant liability for the September 2018 Public Offering warrants at January 31, 2022 and October 31, 2021, the Company used the following inputs in its Monte Carlo simulation model:

	January 31, 2022			October 31, 2021
Exercise Price	$	0.25		$	0.30
Stock Price	$	0.136		$	0.485
Expected Term		2.61 years			2.87 years
Volatility %		118	%		123	%
Risk Free Rate		1.29	%		0.77	%

Private Placement [Member]

Subsidiary, Sale of Stock [Line Items]

SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY

	January 31, 2022			October 31, 2021
Exercise Price	$	0.70		$	0.70
Stock Price	$	0.136		$	0.485
Expected Term		5.00 years			5.00 years
Volatility %		108	%		106	%
Risk Free Rate		1.62	%		1.18	%

TEMPORARY EQUITY (Tables)

3 Months Ended

Jan. 31, 2022

Temporary Equity

SCHEDULE OF PREFERRED STOCK REDEMPTION LIABILITY

In measuring the preferred stock redemption liability at January 31, 2022 (issuance date), the Company used the following inputs in its binomial model:

	January 31, 2022
Exercise Price	$	0.25
Stock Price	$	0.136
Volatility %		105	%
Risk Free Rate		1.00	%

STOCKHOLDERS’ EQUITY (Tables)

3 Months Ended

Jan. 31, 2022

Equity [Abstract]

SUMMARY OF STOCKHOLDERS EQUITY

A summary of the changes in stockholders’ equity for the three months ended January 31, 2022 and 2021 is presented below (in thousands, except share data):

SUMMARY OF STOCKHOLDERS EQUITY

	Shares		Amount		Shares		Amount		Capital		Deficit			Equity
	Preferred Stock				Common Stock				Additional Paid-In		Accumulated			Total Shareholders’
	Shares		Amount		Shares		Amount		Capital		Deficit			Equity
Balance at November 1, 2020		-	$	-		78,074,023	$	78	$	440,840	$	(410,738	)	$	30,180
Beginning balance, value		-	$	-		78,074,023	$	78	$	440,840	$	(410,738	)	$	30,180
Stock-based compensation		-		-		-		-		236		-			236
Advaxis public offerings, net of offering costs		-		-		30,666,665		31		8,519		-			8,550
Warrant exercises		-		-		7,390,000		7		2,579		-			2,586
Net Loss		-		-		-		-		-		(3,977	)		(3,977	)
Balance at January 31, 2021		-	$	-		116,130,688	$	116	$	452,174	$	(414,715	)	$	37,575
Ending balance , value		-	$	-		116,130,688	$	116	$	452,174	$	(414,715	)	$	37,575

	Preferred Stock				Common Stock				Additional Paid-In		Accumulated			Total Shareholders’
	Shares		Amount		Shares		Amount		Capital		Deficit			Equity
Balance at November 1, 2021		-	$	-		145,638,459	$	146	$	467,342	$	(428,600	)	$	38,888
Beginning balance, value		-	$	-		145,638,459	$	146	$	467,342	$	(428,600	)	$	38,888
Stock-based compensation		-		-		-		-		26		-			26
Net Loss		-		-		-		-		-		(365	)		(365	)
Balance at January 31, 2022		-	$	-		145,638,459	$	146	$	467,368	$	(428,965	)	$	38,549
Ending balance, value		-	$	-		145,638,459	$	146	$	467,368	$	(428,965	)	$	38,549

SHARE BASED COMPENSATION (Tables)

3 Months Ended

Jan. 31, 2022

Share-based Payment Arrangement [Abstract]

SUMMARY OF SHARE BASED COMPENSATION EXPENSE

The following table summarizes share-based compensation expense included in the condensed consolidated statements of operations (in thousands):

	Three Months Ended January 31,
	2022		2021
Research and development	$	13	$	57
General and administrative		13		179
Total	$	26	$	236

SUMMARY OF CHANGES IN STOCK OPTION PLAN

A summary of changes in the stock option plan for the three months ended January 31, 2022 is as follows:

SUMMARY OF CHANGES IN STOCK OPTION PLAN

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value (in thousands)
Outstanding as of October 31, 2021		893,946		$	19.32		7.80	$	27
Cancelled or expired		(5,888	)		277.50
Outstanding as of January 31, 2022		888,058		$	17.61		7.55	$	-
Vested and exercisable at January 31, 2022		484,641		$	31.80		6.89	$	-

SUMMARY OF OUTSTANDING AND EXERCISABLE OPTIONS

The following table summarizes information about the outstanding and exercisable options at January 31, 2022:

Options Outstanding								Options Exercisable
				Weighted		Weighted				Weighted		Weighted
				Average		Average				Average		Average
Exercise		Number		Remaining		Exercise		Number		Remaining		Exercise
Price Range		Outstanding		Contractual		Price		Exercisable		Contractual		Price
$	.30-$1.00		672,500		8.29	$	0.54		270,000		8.20	$	0.50
$	1.01-$10.00		55,379		6.80	$	7.47		54,462		6.79	$	7.56
$	10.01-$100.00		90,432		5.97	$	29.02		90,432		5.97	$	29.02
$	100.01-$258.30		69,747		3.07	$	175.51		69,747		3.07	$	175.51

FAIR VALUE (Tables)

3 Months Ended

Jan. 31, 2022

Fair Value Disclosures [Abstract]

SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of January 31, 2022 and October 31, 2021 (in thousands):

	Level 1		Level 2		Level 3		Total
Fair value measured at January 31, 2022
	Level 1		Level 2		Level 3		Total
Financial assets at fair value:
Cash equivalents (money market funds)	$	17,154	$	-	$	-	$	17,154
Total Financial Assets at Fair Value	$	17,154	$	-	$	-	$	17,154

Financial liabilities at fair value:
Preferred stock redemption liability	$	-	$	-	$	87	$	87
Common stock warrant liability, warrants exercisable at $0.25 through September 2024		-		-		7		7
Common stock warrant liability, warrants exercisable at $0.70 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)		-		-		1,120		1,120
Total financial liabilities at fair value	$	-	$	-	$	1,214	$	1,214

	Level 1		Level 2		Level 3		Total
Fair value measured at October 31, 2021
	Level 1		Level 2		Level 3		Total
Financial assets at fair value:
Cash equivalents (money market funds)	$	17,153	$	-	$	-	$	17,153
Total Financial Assets at Fair Value	$	17,153	$	-	$	-	$	17,153

Financial liabilities at fair value:
Common stock warrant liability, warrants exercisable at $0.30 through September 2024	$	-	$	-	$	27	$	27
Common stock warrant liability, warrants exercisable at $0.70 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)		-		-		4,902		4,902
Total financial liabilities at fair value	$	-	$	-	$	4,929	$	4,929

SCHEDULE OF FAIR VALUE MEASURING UNOBSERVABLE INPUTS

	Preferred Stock Redemption Liability		Warrant Liabilities			Total
Fair value at October 31, 2021	$	-	$	4,929		$	4,929
Additions		87		-			87
Change in fair value		-		(3,802	)		(3,802	)
Fair value at January 31, 2022	$	87	$	1,127		$	1,214

NATURE OF OPERATIONS (Details Narrative) - USD ($) $ in Thousands	Jan. 31, 2022	Oct. 31, 2021	Jan. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents, at carrying value	$ 36,480	$ 41,614	$ 33,318

SCHEDULE OF ANTI -DILUTED SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details) - shares	3 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	51,113,455	9,067,153
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	30,225,397	8,014,220
SeriesD Convertable Redeemable Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	20,000,000
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	888,058	1,047,377
Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		5,556

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Details Narrative) - USD ($) $ in Thousands	Jan. 31, 2022	Oct. 31, 2021	Jan. 31, 2021
Restricted cash	$ 5,250
SeriesD Preferred Stock Redemption [Member]
Restricted cash	$ 5,250

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($) $ in Thousands	Jan. 31, 2022	Oct. 31, 2021
Property, Plant and Equipment [Abstract]
Laboratory equipment	$ 179	$ 179
Computer equipment	241	241
Total property and equipment	420	420
Accumulated depreciation and amortization	(320)	(302)
Net property and equipment	$ 100	$ 118

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 18	$ 192

SUMMARY OF INTANGIBLE ASSETS (Details) - USD ($) $ in Thousands	Jan. 31, 2022	Oct. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 4,769	$ 4,836
Licenses	777	777
Software	98	98
Total intangibles	5,644	5,711
Accumulated amortization	(2,406)	(2,357)
Intangible assets	$ 3,238	$ 3,354

SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS (Details) - USD ($) $ in Thousands	Jan. 31, 2022	Oct. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
2022 (Remaining)	$ 211
2023	282
2024	282
2025	282
2026	282
Thereafter	1,899
Total	$ 3,238	$ 3,354

INTANGIBLE ASSETS (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Goodwill [Line Items]
Book value patent applications, net	$ 104
Intangible asset amortization expense	70	67
General and Administrative Expense [Member]
Goodwill [Line Items]
Book value patent applications, net	104
Intangible asset amortization expense	$ 70	$ 67

SUMMARY OF ACCRUED EXPENSES (Details) - USD ($) $ in Thousands	Jan. 31, 2022	Oct. 31, 2021
Payables and Accruals [Abstract]
Salaries and other compensation	$ 170	$ 55
Vendors	1,524	1,968
Professional fees	237	613
Other	200	200
Total accrued expenses	$ 2,131	$ 2,836

SCHEDULE OF SUPPLEMENTAL BALANCE SHEET RELATED TO LEASES (Details) - USD ($) $ in Thousands	Jan. 31, 2022	Oct. 31, 2021	Mar. 26, 2021	Mar. 25, 2021
Leases
Operating lease right-of-use assets	$ 33	$ 40	$ 4,500	$ 43
Operating lease liability	29	28
Operating lease liability, net of current portion	5	12
Total operating lease liabilities	$ 34	$ 40	$ 5,600	$ 43

SCHEDULE OF LEASE EXPENSES (Details) - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Leases
Operating lease cost	$ 7	$ 290
Variable lease cost	9	437
Total lease expense	$ 16	$ 727

SCHEDULE OF OTHER INFORMATION RELATED TO LEASES (Details)	Jan. 31, 2022	Oct. 31, 2021
Leases
Weighted-average remaining lease term	1 year 2 months 12 days	1 year 4 months 24 days
Weighted-average discount rate	3.79%	3.79%

SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES (Details) - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Leases
Cash paid for operating lease liabilities	$ 7	$ 324

SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELLABLE LEASES (Details) - USD ($) $ in Thousands	Jan. 31, 2022	Oct. 31, 2021	Mar. 26, 2021	Mar. 25, 2021
Leases
2022 (Remaining)	$ 22
2023	13
Total minimum lease payments	35
Less: Imputed interest	(1)
Total	$ 34	$ 40	$ 5,600	$ 43

LEASES (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended
LEASES (Details Narrative) - USD ($)	Mar. 26, 2021	Mar. 25, 2021	Jan. 31, 2022	Oct. 31, 2021
Leases
Lease expiration date			Nov. 30, 2025
Lease termination	$ 1,000,000
Security deposit			$ 182,000
Net payment for termination fee	818,000
Operating lease, Right of use asset	4,500,000	$ 43,000	33,000	$ 40,000
Operating lease liability	5,600,000	$ 43,000	$ 34,000	$ 40,000
Net gain on leases	100,000
Rent paid	$ 29,000
Lease expiration date		Mar. 25, 2022
Lessee finance lease renewal term date		Mar. 25, 2023

COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Details) - $ / shares shares in Thousands	3 Months Ended	12 Months Ended
	Jan. 31, 2022	Oct. 31, 2021
Offsetting Assets [Line Items]
Exercise Price	$ 0.25	$ 0.30
Grand Total Number of Shares Underlying Warrants	30,225,397	30,225,397
Exercise Price Range One [Member]
Offsetting Assets [Line Items]
Exercise Price	$ 281.25	$ 281.25
Grand Total Number of Shares Underlying Warrants	25	25
Type of Financing	Other warrants	Other warrants
Exercise Price Range Two [Member]
Offsetting Assets [Line Items]
Exercise Price	$ 0.25	$ 0.25
Grand Total Number of Shares Underlying Warrants	70,297	70,297
Type of Financing	September 2018 Public Offering	September 2018 Public Offering
Expiration Date	July 2024	July 2024
Exercise Price Range Three [Member]
Offsetting Assets [Line Items]
Exercise Price	$ 2.80	$ 2.80
Grand Total Number of Shares Underlying Warrants	327,338	327,338
Type of Financing	July 2019 Public Offering	July 2019 Public Offering
Expiration Date	September 2024	September 2024
Exercise Price Range Four [Member]
Offsetting Assets [Line Items]
Exercise Price	$ 0.35	$ 0.35
Grand Total Number of Shares Underlying Warrants	4,578,400	4,578,400
Type of Financing	November 2020 Public Offering	November 2020 Public Offering
Expiration Date	November 2025	November 2025
Exercise Price Range Five [Member]
Offsetting Assets [Line Items]
Exercise Price	$ 0.70	$ 0.70
Grand Total Number of Shares Underlying Warrants	11,244,135	11,244,135
Type of Financing	April 2021 Registered Direct Offering (Accompanying Warrants)	April 2021 Registered Direct Offering (Accompanying Warrants)
Expiration Date	April 2026	April 2026
Exercise Price Range Six [Member]
Offsetting Assets [Line Items]
Exercise Price	$ 0.70	$ 0.70
Grand Total Number of Shares Underlying Warrants	14,005,202	14,005,202
Type of Financing	April 2021 Private Placement (Private Placement Warrants)	April 2021 Private Placement (Private Placement Warrants)
Expiration Date	5 years after the date such warrants become exercisable, if ever	5 years after the date such warrants become exercisable, if ever

SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY (Details)	Jan. 31, 2022 $ / shares	Oct. 31, 2021 $ / shares
Exercise Price	$ 0.25	$ 0.30
Private Placement [Member]
Exercise Price	0.70	0.70
Warrant Liability [Member]
Exercise Price	0.25	0.30
Stock Price	$ 0.136	$ 0.485
Warrant Liability [Member] \| Measurement Input, Expected Term [Member]
Expected Term	2 years 7 months 9 days	2 years 10 months 13 days
Warrant Liability [Member] \| Measurement Input, Price Volatility [Member]
Measurement input percentage	118	123
Warrant Liability [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement input percentage	1.29	0.77
Warrant Liability [Member] \| Private Placement [Member]
Exercise Price	$ 0.70	$ 0.70
Stock Price	$ 0.136	$ 0.485
Warrant Liability [Member] \| Private Placement [Member] \| Measurement Input, Expected Term [Member]
Expected Term	5 years	5 years
Warrant Liability [Member] \| Private Placement [Member] \| Measurement Input, Price Volatility [Member]
Measurement input percentage	108	106
Warrant Liability [Member] \| Private Placement [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement input percentage	1.62	1.18

COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Details Narrative) - USD ($)	3 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Oct. 31, 2021	Jun. 03, 2021
Number of warrants to purchase common stock	30,225,397,000		30,225,397,000
Warrant exercise price per share	$ 0.25		$ 0.30
Common stock par or stated value per share	$ 0.001		$ 0.001
Common stock shares authorized	170,000,000		170,000,000
Fair value of the warrant liability	$ 1,127,000		$ 4,929,000
Income on fair value of warrants	$ 3,802,000	$ 27,000
Private Placement [Member]
Warrant exercise price per share	$ 0.70		$ 0.70
IPO [Member]
Common stock shares authorized	300,000,000
Minimum [Member]
Common stock shares authorized				170,000,000
Maximum [Member]
Common stock shares authorized				300,000,000
Warrant [Member]
Warrants outstanding	30,225,397		30,225,397
Number of warrants to purchase common stock	30,225,397		30,225,397
Warrant [Member] \| Minimum [Member]
Warrant exercise price per share	$ 0.30
Warrant [Member] \| Maximum [Member]
Warrant exercise price per share	$ 281.25
Equity Warrants [Member]
Warrants outstanding	30,225,397
Number of warrants to purchase common stock			16,149,898
Warrant Liability [Member]
Warrant exercise price per share	$ 0.25		$ 0.30
Warrant Liability [Member] \| Private Placement [Member]
Warrants outstanding	30,225,397		30,225,397
Number of warrants to purchase common stock	14,075,499		14,075,499
Warrant exercise price per share	$ 0.70		$ 0.70
Warrant Liability [Member] \| Minimum [Member]
Warrant exercise price per share		$ 0.25
Warrant Liability [Member] \| Maximum [Member]
Warrant exercise price per share		$ 22.50

SCHEDULE OF PREFERRED STOCK REDEMPTION LIABILITY (Details)	Jan. 31, 2022
Measurement Input, Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input percentage	0.25
Measurement Input, Share Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input percentage	0.136
Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input percentage	105
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input percentage	1.00

TEMPORARY EQUITY (Details Narrative)	1 Months Ended	3 Months Ended
TEMPORARY EQUITY (Details Narrative)	Jan. 31, 2022 USD ($) Integer $ / shares shares	Jan. 31, 2022 USD ($) $ / shares	Jan. 31, 2021 USD ($)	Oct. 31, 2021 USD ($)
Subsidiary, Sale of Stock [Line Items]
Stated value			$ 8,550,000
Issue discount	5.00%
Proceeds from issuance or estimated offering	$ 4,312,000
Number of votes per share \| Integer	30,000
Temporary equity stock stated value accumulated dividends		105.00%
Temporary equity stock stated value accumulated dividends on extension		110.00%
Payments for proceeds from escrow offering	$ 4,750,000
Escrow deposit	500,000	$ 500,000
Temporary equity stock stated value accumulated dividends on extension		105.00%
Temporary equity, carrying amount, attributable to parent	4,225,000	$ 4,225,000
Preferred stock, redemption amount	$ 87,000	$ 87,000
Series D Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock conversion price \| $ / shares	$ 0.25	$ 0.25
Private Placement [Member] \| Institutional Investors [Member] \| Series D Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued \| shares	1,000,000
Stated value	$ 5,000,000
Share purchase price \| $ / shares	$ 4.75	$ 4.75

SUMMARY OF STOCKHOLDERS EQUITY (Details) - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, value	$ 38,888	$ 30,180
Stock-based compensation	26	236
Advaxis public offerings, net of offering costs		8,550
Warrant exercises		2,586
Net Loss	(365)	(3,977)
Ending balance, value	38,549	37,575
Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, value
Beginning balance, shares
Stock-based compensation
Stock-based compensation, shares
Advaxis public offerings, net of offering costs
Advaxis public offerings, net of offering costs, shares
Warrant exercises
Net Loss
Ending balance, value
Ending balance, shares
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, value	$ 146	$ 78
Beginning balance, shares	145,638,459	78,074,023
Stock-based compensation
Stock-based compensation, shares
Advaxis public offerings, net of offering costs		$ 31
Advaxis public offerings, net of offering costs, shares		30,666,665
Warrant exercises		$ 7
Warrant exercises, shares		7,390,000
Net Loss
Ending balance, value	$ 146	$ 116
Ending balance, shares	145,638,459	116,130,688
Additional Paid-in Capital [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, value	$ 467,342	$ 440,840
Stock-based compensation	26	236
Advaxis public offerings, net of offering costs		8,519
Warrant exercises		2,579
Net Loss
Ending balance, value	467,368	452,174
Retained Earnings [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, value	(428,600)	(410,738)
Stock-based compensation
Advaxis public offerings, net of offering costs
Warrant exercises
Net Loss	(365)	(3,977)
Ending balance, value	$ (428,965)	$ (414,715)

SUMMARY OF SHARE BASED COMPENSATION EXPENSE (Details) - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	$ 26	$ 236
Research and Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	13	57
General and Administrative Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	$ 13	$ 179

SUMMARY OF CHANGES IN STOCK OPTION PLAN (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Jan. 31, 2022 USD ($) $ / shares shares
Share-based Payment Arrangement [Abstract]
Shares Outstanding, Beginning Balance \| shares	893,946
Weighted Average Exercise Price, Outstanding, Beginning \| $ / shares	$ 19.32
Weighted Average Remaining Contractual Life In Years, Beginning	7 years 9 months 18 days
Aggregate Intrinsic Value, Beginning \| $	$ 27
Shares, Cancelled or Expired \| shares	(5,888)
Weighted Average Exercise Price, Cancelled or Expired \| $ / shares	$ 277.50
Shares, Outstanding, Ending Balance \| shares	888,058
Weighted Average Exercise Price, Outstanding, Ending \| $ / shares	$ 17.61
Weighted Average Remaining Contractual Life In Years, Ending Balance	7 years 6 months 18 days
Aggregate Intrinsic Value, Ending \| $
Shares, Vested and Exercisable \| shares	484,641
Weighted Average Exercise Price, Vested and Exercisable \| $ / shares	$ 31.80
Weighted Average Remaining Contractual Life In Years, Vested and Exercisable	6 years 10 months 20 days
Aggregate Intrinsic Value, Vested and Exercisable \| $

SUMMARY OF OUTSTANDING AND EXERCISABLE OPTIONS (Details)	3 Months Ended
	Jan. 31, 2022 $ / shares shares
Exercise Price Range One [Member]
Offsetting Assets [Line Items]
Exercise Price Range, lower limit	$ 0.30
Exercise Price Range, upper limit	$ 1.00
Number Outstanding, Options Outstanding \| shares	672,500
Weighted Average Remaining Contractual, Options Outstanding	8 years 3 months 14 days
Weighted Average Exercise Price, Options Outstanding	$ 0.54
Number Outstanding, Options Exercisable \| shares	270,000
Weighted Average Remaining Contractual Term Exercisable, Options Exercisable	8 years 2 months 12 days
Weighted Average Exercise Price, Options Exercisable	$ 0.50
Exercise Price Range Two [Member]
Offsetting Assets [Line Items]
Exercise Price Range, lower limit	1.01
Exercise Price Range, upper limit	$ 10.00
Number Outstanding, Options Outstanding \| shares	55,379
Weighted Average Remaining Contractual, Options Outstanding	6 years 9 months 18 days
Weighted Average Exercise Price, Options Outstanding	$ 7.47
Number Outstanding, Options Exercisable \| shares	54,462
Weighted Average Remaining Contractual Term Exercisable, Options Exercisable	6 years 9 months 14 days
Weighted Average Exercise Price, Options Exercisable	$ 7.56
Exercise Price Range Three [Member]
Offsetting Assets [Line Items]
Exercise Price Range, lower limit	10.01
Exercise Price Range, upper limit	$ 100.00
Number Outstanding, Options Outstanding \| shares	90,432
Weighted Average Remaining Contractual, Options Outstanding	5 years 11 months 19 days
Weighted Average Exercise Price, Options Outstanding	$ 29.02
Number Outstanding, Options Exercisable \| shares	90,432
Weighted Average Remaining Contractual Term Exercisable, Options Exercisable	5 years 11 months 19 days
Weighted Average Exercise Price, Options Exercisable	$ 29.02
Exercise Price Range Four [Member]
Offsetting Assets [Line Items]
Exercise Price Range, lower limit	100.01
Exercise Price Range, upper limit	$ 258.30
Number Outstanding, Options Outstanding \| shares	69,747
Weighted Average Remaining Contractual, Options Outstanding	3 years 25 days
Weighted Average Exercise Price, Options Outstanding	$ 175.51
Number Outstanding, Options Exercisable \| shares	69,747
Weighted Average Remaining Contractual Term Exercisable, Options Exercisable	3 years 25 days
Weighted Average Exercise Price, Options Exercisable	$ 175.51

SHARE BASED COMPENSATION (Details Narrative) $ in Millions	3 Months Ended
SHARE BASED COMPENSATION (Details Narrative) $ in Millions	Jan. 31, 2022 USD ($) shares
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Unrecognized compensation cost related to outstanding stock options \| $	$ 125,000.0
Unrecognized compensation cost related to non-vested remaining weighted average vesting period	1 year 4 months 17 days
Chief Executive Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Share-based compensation arrangement by share-based payment award, options, nonvested, number of shares \| shares	73,777

LICENSING AGREEMENTS (Details Narrative) - USD ($)			3 Months Ended
LICENSING AGREEMENTS (Details Narrative) - USD ($)	Apr. 30, 2020	Sep. 04, 2018	Jan. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone achievement, description			the Company received an aggregate of $1,615,000 from OS Therapies upon achievement of the funding milestone set forth in the license agreement
Development, License and Supply Agreement [Member] \| OS Therapies [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	$ 25,000
Funding milestone payment		$ 2,337,500

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

+ Details

SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) - USD ($) $ / shares in Units, $ in Thousands	Jan. 31, 2022	Oct. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Financial Assets at Fair Value	$ 17,154	$ 17,153
Preferred stock redemption liability	87
Common stock warrant liability, warrants exercisable at $0.30 through September 2024	$ 1,127	$ 4,929
Warrant exercise price per share	$ 0.25	$ 0.30
Total financial liabilities at fair value	$ 1,214	$ 4,929
Private Placement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant exercise price per share	$ 0.70	$ 0.70
Common stock warrant liability, warrants exercisable at $0.70 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)	$ 1,120	$ 4,902
Through September Two Thousand Twenty Four [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Common stock warrant liability, warrants exercisable at $0.30 through September 2024	7	27
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents (money market funds)	17,154	17,153
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Financial Assets at Fair Value	17,154	17,153
Preferred stock redemption liability
Total financial liabilities at fair value
Fair Value, Inputs, Level 1 [Member] \| Private Placement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Common stock warrant liability, warrants exercisable at $0.70 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)
Fair Value, Inputs, Level 1 [Member] \| Through September Two Thousand Twenty Four [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Common stock warrant liability, warrants exercisable at $0.30 through September 2024
Fair Value, Inputs, Level 1 [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents (money market funds)	17,154	17,153
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Financial Assets at Fair Value
Preferred stock redemption liability
Total financial liabilities at fair value
Fair Value, Inputs, Level 2 [Member] \| Private Placement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Common stock warrant liability, warrants exercisable at $0.70 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)
Fair Value, Inputs, Level 2 [Member] \| Through September Two Thousand Twenty Four [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Common stock warrant liability, warrants exercisable at $0.30 through September 2024
Fair Value, Inputs, Level 2 [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents (money market funds)
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Financial Assets at Fair Value
Preferred stock redemption liability	87
Total financial liabilities at fair value	1,214	4,929
Fair Value, Inputs, Level 3 [Member] \| Private Placement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Common stock warrant liability, warrants exercisable at $0.70 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)	1,120	4,902
Fair Value, Inputs, Level 3 [Member] \| Through September Two Thousand Twenty Four [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Common stock warrant liability, warrants exercisable at $0.30 through September 2024	7	27
Fair Value, Inputs, Level 3 [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents (money market funds)

SCHEDULE OF FAIR VALUE MEASURING UNOBSERVABLE INPUTS (Details) $ in Thousands	3 Months Ended
	Jan. 31, 2022 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair Value, Measurement , Beginning Balance	$ 4,929
Fair Value, Measurement, Additions	87
Fair Value, Measurement, Change in fair value	(3,802)
Fair Value, Measurement , Ending Balance	1,214
Preferred Stock Redemption Liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair Value, Measurement , Beginning Balance
Fair Value, Measurement, Additions	87
Fair Value, Measurement, Change in fair value
Fair Value, Measurement , Ending Balance	87
Warrant Liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair Value, Measurement , Beginning Balance	4,929
Fair Value, Measurement, Additions
Fair Value, Measurement, Change in fair value	(3,802)
Fair Value, Measurement , Ending Balance	$ 1,127